Ameriprise’s Generate Biomedicines GENB Stock Holding History
Bought
Maintained
Sold
Other funds holding GENB
Ameriprise's GENB Position: Q3 2026 in Review
Ameriprise reduced its Generate Biomedicines (GENB) stake by 6.1% in Q3 2026, selling an estimated $85.1K and leaving 85,567 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3329.
Ameriprise first reported a position in GENB in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.54M in Q2 2026. 109 funds tracked by Wall St. Rank hold GENB as of Q3 2026.
- Ameriprise held 85,567 shares of Generate Biomedicines worth $1.29M as of Q3 2026.
- Ameriprise sold 5,533 Generate Biomedicines shares in Q3 2026, an estimated $85.1K.
- Generate Biomedicines made up ﹤0.01% of Ameriprise's portfolio in Q3 2026, its #3329 holding.
- Ameriprise first reported a position in Generate Biomedicines in Q1 2026 and has held it in 3 quarters since.
- Ameriprise's Generate Biomedicines position peaked at $1.54M in Q2 2026.
- 109 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.
Based on Ameriprise's 13F filing for Q3 2026, filed 16 Nov 2026.